Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2− advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2
| العنوان: | Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2− advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2 |
|---|---|
| المؤلفون: | David Cameron, Vikash Kumar Sharma, Chandroday Biswas, Cathy Clarke, David Chandiwana, Purnima Pathak |
| المصدر: | Cameron, D A, Kumar Sharma, V, Biswas, C, Clarke, C, Chandiwanna, D & Pathak, P 2023, ' Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2− advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2 ', Journal of Medical Ethics . https://doi.org/10.1080/13696998.2023.218205 |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Health Policy |
| وصف الملف: | application/pdf |
| اللغة: | English |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d029006b4975578645d5ad73d861316 https://hdl.handle.net/20.500.11820/b270052c-1c48-43fa-bf9b-4c44f8cad630 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....3d029006b4975578645d5ad73d861316 |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |